Methods for treatment using anti-NMU agents

A method of increasing circulating insulin in an individual in need thereof, the method comprising:

• administering to the individual, an anti-NMU antibody or antigen binding region thereof that reduces binding between NMU and NMUR1, at a dose effective to increase the amount of circulating insulin in the individual, wherein the anti-NMU antibody or antigen binding region thereof comprises:
• (i) a light chain comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs:
• 18-20, respectively, and a heavy chain comprising a CDR-H1, CDR-H2, and CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs:
• 26-28;
• or
• (ii) a light chain comprising a CDR-L1, CDR-L2, and CDR-L3 comprising the amino acid sequences set forth in SEQ ID NOs:
• 2-4, respectively, and a heavy chain comprising a CDR-H1, CDR-H2, and CDR-H3 comprising the amino acid sequences set forth in SEQ ID NOs:
• 10-12.

A method of increasing circulating insulin in an individual in need thereof, the method comprising:

• administering to the individual, an anti-NMU antibody or antigen binding region thereof that reduces binding between NMU and NMUR1, at a dose effective to increase the amount of circulating insulin in the individual, wherein the anti-NMU antibody or antigen binding region thereof comprises a first CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 18, a second CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 19, a third CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 20, a fourth CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 26, a fifth CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 27, and a sixth CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 28.

A method of increasing circulating insulin in an individual in need thereof, the method comprising:

• administering to the individual, an anti-NMU antibody or antigen binding region thereof that reduces binding between NMU and NMUR1, at a dose effective to increase the amount of circulating insulin in the individual, wherein the anti-NMU antibody or antigen binding region thereof comprises a first CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 2, a second CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 3, a third CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 4, a fourth CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 10, a fifth CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 11, and a sixth CDR comprising the amino acid sequence set forth in SEQ ID NO:
• 12.